Food Effects Study of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- AUCinf
研究概览
简要总结
A single-center, randomized, open, single-dose, two-cycle, two-sequence, cross-over study was conducted to evaluate the effect of food on the pharmacokinetic characteristics of GST-HG171 in combination with Ritonavir.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent before the trial and fully understand the content, process and possible adverse reactions of the trial;
- •Ability to complete research in accordance with test plan requirements;
- •Subjects (including partners) are willing to take effective pregnancy avoidance measures within 6 months after screening to the last study drug administration;
- •Male and female healthy subjects aged 18 to 50 years (including 18 and 50 years old);
- •Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. Body mass index (BMI) = body weight (kg) / height 2 (m2), body mass index is in the range of 18 ~ 28 kg / m2 (including critical value);
- •Physical examination, normal or abnormal vital signs have no clinical significance
排除标准
- •Allergies (multiple drugs and food allergies);
- •Those who smoked more than 5 cigarettes per day in the 3 months before the trial;
- •Have a history of drug abuse and / or alcoholism (drink 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
- •Blood donation or massive blood loss (> 400 mL) within three months before screening;
- •Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, including a history of frequent nausea or vomiting caused by any cause;
- •Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- •Have taken the study drug or participated in the drug clinical trial within three months before taking the study drug;
- •Have Intended to take any drug that changes the activity of drug metabolizing enzyme 28 days before screening or during the study, including strong inhibitors and inducers that affect the metabolizing enzyme;
- •Took any prescription drugs or herbs within 14 days before screening, or took over-the-counter drugs or any vitamin products within 7 days before screening;
- •Vaccinated within 14 days before screening or planned to be vaccinated during the study;
- •Those who have taken special diets (including dragon fruit, mango, grapefruit, etc.) or have vigorous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 2 weeks before screening;
- •Those who cannot tolerate high fat (about 50% of the total calories) and high calorie (about 800~1000 calories) standard meals (only applies to subjects participating in the food effect study);
- •Abnormal ECG has clinical significance;
- •Female subjects were breastfeeding or had a positive serum pregnancy result during the screening period or during the study;
- •Clinical laboratory examinations are abnormal and clinically significant, or find the following diseases with clinical significance (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, Immune, mental or cardiovascular disease) within 6 months before screening;
- •Positive screening for viral hepatitis (including hepatitis B and C), AIDS antigen / antibody, and Treponema pallidum antibody;
- •Acute disease or concomitant medication occurs from the screening stage to before study medication;
- •Ingested chocolate, any caffeinated or xanthine-rich food or drink 24 hours before taking the study drug;
- •People who have a positive urine drug screen or have a history of drug abuse or have used drugs within the past five years;
- •The investigator believes that there are other subjects who are not suitable for participating in this trial.
研究组 & 干预措施
Treatment A
Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
干预措施: GST-HG171/ritonavir (Drug)
Treatment A
Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
干预措施: ritonavir (Drug)
Treatment B
Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
干预措施: GST-HG171/ritonavir (Drug)
Treatment B
Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
干预措施: ritonavir (Drug)
结局指标
主要结局
AUCinf
时间窗: Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of GST-HG171
AUClast
时间窗: Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose
Area Under the Curve From Time Zero o Last quantifiable concentration (AUClast) of GST-HG171
Cmax
时间窗: Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose
Maximum Observed Plasma Concentration (Cmax) of GST-HG171
次要结局
- urine(120 hours from GST-HG171 administration)
- feces(120 hours from GST-HG171 administration)